A Review of Phase 3 Trials of Dupilumab for the Treatment of Atopic Dermatitis in Adults, Adolescents, and Children Aged 6 and Up

Atopic dermatitis (AD) is a chronic pruritic skin disease that can have a profound negative impact on patients’ quality of life, especially in cases of inadequate disease control. Dupilumab, a dual inhibitor of IL-4 and IL-13 signaling, is approved in the United States for the treatment of moderate-...

Descripción completa

Detalles Bibliográficos
Autores principales: Cather, Jennifer, Young, Melodie, DiRuggiero, Douglas C., Tofte, Susan, Williams, Linda, Gonzalez, Tayler
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9464283/
https://www.ncbi.nlm.nih.gov/pubmed/36028787
http://dx.doi.org/10.1007/s13555-022-00778-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9464283/
https://www.ncbi.nlm.nih.gov/pubmed/36028787
http://dx.doi.org/10.1007/s13555-022-00778-y

Ejemplares similares